StemCell Therapy

One of the most dreaded consequences of cancer is when the disease metastasizes -- meaning it spreads from the primary site where it started to other parts of the body. But University of California, Riverside (UCR) scientists have announced what could be a major breakthrough in halting metastasis. They've discovered components in pomegranate juice that inhibit the movement of cancer cells and weaken the attraction of malignant cells to a chemical signal that has been shown to promote metastasis.

The UCR findings were just presented at the American Society for Cell Biology's 50th Annual Meeting, which is being held in Philadelphia. Specifically, the research team from the UCR laboratory of Manuela Martins-Green, Ph.D., found that pomegranate juice seems to block the spread of prostate cancer cells to the bone. The group is planning additional tests to determine the effects of various doses of the natural pomegranate compounds and whether there are any side effects. Read more...

Cardiofy Heart Care Supplement

Aids researchers and advocates were devastated in 2007, when a much anticipated vaccine against HIV unexpectedly failed to protect anyone in a clinical trial of 3,000 people. Even worse, the experimental inoculation, developed with money from the Merck pharmaceutical company and the National Institute of Allergy and Infectious Diseases, actually increased the chances that some people would later acquire HIV. Millions of dollars and more than a decade of research had gone into creating the vaccine. Meanwhile, in that same 10-year period, 18 million people died of AIDS, and millions more were infected.

The Merck vaccine failed in large part because investigators do not yet know how to create the perfect vaccine. Yes, a number of vaccines have been spectacularly successful. Think of polio and smallpox. In truth, though, luck played a big role in those successes. Based on limited knowledge of the immune system and of the biology of a pathogen, investigators made educated guesses at vaccine formulations that might work and then, perhaps after some tinkering, had the good fortune to be proved right when the vaccine protected people. But all too often lack of insight into the needed immune response leads to disappointment, with a vaccine candidate recognized as ineffective only after a large human trial has been performed.

[More]

Poor sanitation can foster transmission of all sorts of nasty bacterial bugs. But a new study has found that among common bacteria, antibiotic resistance is brewing in the New Delhi water supply--and spreading in at least 20 strains, including some that cause dysentery and cholera. [More]

Data from successful animal study using liver cells derived from human parthenogenetic stem cells to be presented at two upcoming scientific conferences

Company also announces collaboration with Cedars-Sinai Medical Center for liver disease research, and completion of research on cytochrome P450 activity

International Stem Cell Corporation (OTCBB:ISCO) (ISCO) announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells (hpSC). In the transplantation mouse model, inoculated cells were capable of engrafting and surviving in specific niches within the liver, and were further developing into cells with essential hepatocyte-like features. Moreover, the transplanted cells could be identified in recipient tissue for a prolonged period of time.

The findings of these studies will be presented at the annual meeting of American Society of Gene & Cell Therapy, May 18-21 in Seattle, and at the International Society for Stem Cell Research annual conference, June 15-18 in Toronto.

"These results mark the achievement of a key milestone in our preclinical research," said Andrey Semechkin, Ph.D., ISCO's Chief Executive Officer. "Specifically, we have perfected the technique to transplant hepatocytes, an extremely fragile cell type, into the liver of animals, which is an easily injured organ. This preclinical research helps us develop our collaborations with clinics."

Nikolay Turovets, Ph.D., ISCO's Director of Research and Therapeutic Development commented "The next phase of research is to conduct experiments to demonstrate the ability of the transplanted cells to perform the vital functions of normal hepatocytes and, accordingly, their ability to modify disease by restoring the missing function of a patient's diseased liver."

The Company also announces the signing of a joint collaboration agreement with Cedars-Sinai Medical Center in Los Angeles to conduct research to develop therapies for liver diseases, in particular urea cycle disorders. Jeffrey Fair, MD., a liver transplant surgeon and Director of Translational Research for the Cedars-Sinai Comprehensive Transplant Center and Department of Surgery, will lead the Cedars-Sinai research team.

Dr. Fair said, "Urea cycle disorders are genetic deficiencies of liver function, which mostly affect newborns and oftentimes cause catastrophic neurological injury. It has been shown that transplantation of donor hepatocytes can save patient lives. Therefore, derivation of hepatocytes from hpSCs that can be immune-matched to the patient is a very pressing goal."

The Company also announces the completion of research focused on the investigation of cytochrome P450 activity and corresponding genes in hepatocytes derived from hpSC. According to the results, the differentiation technology developed by ISCO allows the creation of hepatocytes in the fetal stage of development. This research may contribute to the design of a product for future drug testing and discovery.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, research and development goals and related potential therapeutic treatments, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Nikolay Turovets, Ph.D.
Director, Research and Therapeutic Development
nturovets@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today the selection of the Richards Partners as agency of record for its wholly owned subsidiary Lifeline Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin care products based on its proprietary stem cell technology. Based in Dallas, the Richards Partners is the nation's largest independent branding agency.

Lifeline's skin care products were developed by a team of ISCO research scientists in collaboration with world-renowned cosmetic experts, and offer a comprehensive approach to skin care using patent pending moisture serums for day and night use. Made with human parthenogenetic stem cell extracts, the serums deliver anti-aging benefits, resulting in healthier and younger-looking skin. These products were launched in November 2010 and are available for purchase through the http://www.lifelineskincare.com website and selected luxury spas across the United States.

Adding Richards Partners to the Lifeline Skin Care^TM team is part of Lifeline's plan to build on its initial successful product launch last year, and the Web based sales that have followed, by initiating a series of new marketing campaigns to further develop the Lifeline Skin Care^TMbrand identity. These new marketing initiatives include traditional print and news media campaigns, as well as a new digital strategy focused on Internet and social media. "We are looking forward to working closely with the Richards Partners and leveraging their expertise in these areas to enhance the profile of Lifeline Skin Care^TM and its revolutionary new skin care products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally recognizable brand is a long-term process and this is an important step towards creating Lifeline's name. We believe this is a good time to begin these campaigns and continue our sales momentum resulting from our successful initial launch," Dr. Semechkin continued.

As previously announced the Mauldin Group, Lifeline's marketing partner, will be managing the day to day relationship with the Richards Partners and planning additional direct marketing initiatives similar to the successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing partner of Lifeline Skin Care^TM, says, "We're excited about working together with Richards Partners. We believe the collaboration will provide additional momentum and increase brand recognition for Lifeline Skin Care^TM and help educate the public about the revolutionary science behind these products."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

International Stem Cell Corporation (OTCBB:ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today the selection of the Richards Partners as agency of record for its wholly owned subsidiary Lifeline Skin Care, Inc. ("Lifeline"). Lifeline offers luxury anti-aging skin care products based on its proprietary stem cell technology. Based in Dallas, the Richards Partners is the nation's largest independent branding agency.

Lifeline's skin care products were developed by a team of ISCO research scientists in collaboration with world-renowned cosmetic experts, and offer a comprehensive approach to skin care using patent pending moisture serums for day and night use. Made with human parthenogenetic stem cell extracts, the serums deliver anti-aging benefits, resulting in healthier and younger-looking skin. These products were launched in November 2010 and are available for purchase through the http://www.lifelineskincare.com website and selected luxury spas across the United States.

Adding Richards Partners to the Lifeline Skin Care^TM team is part of Lifeline's plan to build on its initial successful product launch last year, and the Web based sales that have followed, by initiating a series of new marketing campaigns to further develop the Lifeline Skin Care^TMbrand identity. These new marketing initiatives include traditional print and news media campaigns, as well as a new digital strategy focused on Internet and social media. "We are looking forward to working closely with the Richards Partners and leveraging their expertise in these areas to enhance the profile of Lifeline Skin Care^TM and its revolutionary new skin care products," says Lifeline CEO Ruslan Semechkin, PhD. "Building a globally recognizable brand is a long-term process and this is an important step towards creating Lifeline's name. We believe this is a good time to begin these campaigns and continue our sales momentum resulting from our successful initial launch," Dr. Semechkin continued.

As previously announced the Mauldin Group, Lifeline's marketing partner, will be managing the day to day relationship with the Richards Partners and planning additional direct marketing initiatives similar to the successful initial launch in 2010. Tiffani Mauldin-Frederick, marketing partner of Lifeline Skin Care^TM, says, "We're excited about working together with Richards Partners. We believe the collaboration will provide additional momentum and increase brand recognition for Lifeline Skin Care^TM and help educate the public about the revolutionary science behind these products."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

http://www.cellmedicine.com

See the original post:
Stem Cell Therapy for Type II Diabetes

Join Evan Snyder, MD, Ph.D., from the Burnham Institute for Medical Research, for a look at the possible therapeutic benefits of neural stem cells (NSCs) in various mouse models of central nervous system (CNS) injury and degeneration. NSCs may migrate to degenerating regions, thus replacing dying neural cells and benefiting those with CNS injuries. In addition, NSCs may serve as vehicles for gene delivery and appear capable of simultaneous neural cell replacement and gene therapy.

See the rest here:
SIRA: Could Stem Cell Therapy Renew Your Body Cells?

SIRA: Could Stem Cell Therapy Renew Your Body Cells? without comments. Join Evan Snyder, MD, Ph.D., from the Burnham Institute for Medical Research, for a look at the possible ...

The rest is here:
SIRA: Could Stem Cell Therapy Renew Your Body Cells? – Affordable ...

Stem cell therapy done at neurogen brain and spine institute pvt ltd. Tell: +91 9920 200 400 , 022 25281610 , 022 25283706

Read the original post:
Stem Cell Therapy for Cerebral Palsy

Stem Cell Therapy for your pet. For a FREE pet evaluation.

View original post here:
Is Stem Cell Therapy right for your pet

Cancers often spread from their primary site (the part of the body in which the cancer started) to one or more metastatic sites (other parts of the body). Cancers are named according to their primary site, regardless of where in the body they spread. For example, a lung cancer that spreads to the lymph nodes, adrenal glands, and the liver is still classified as lung cancer and not as a lymphoma (cancer of the lymph nodes), adrenal cancer, or liver cancer.

A small number of cancers first appear in one or more metastatic sites, and the primary site is not known. These cancers are called cancer of unknown primary (CUP). The primary site of some of these cancers may eventually be found by additional tests. When this happens, they are no longer considered a cancer of unknown primary and are renamed according to the newly discovered site of origin. Read more...

Immunice for Immune Support

Cancers often spread from their primary site (the part of the body in which the cancer started) to one or more metastatic sites (other parts of the body). Cancers are named according to their primary site, regardless of where in the body they spread. For example, a lung cancer that spreads to the lymph nodes, adrenal glands, and the liver is still classified as lung cancer and not as a lymphoma (cancer of the lymph nodes), adrenal cancer, or liver cancer.

A small number of cancers first appear in one or more metastatic sites, and the primary site is not known. These cancers are called cancer of unknown primary (CUP). The primary site of some of these cancers may eventually be found by additional tests. When this happens, they are no longer considered a cancer of unknown primary and are renamed according to the newly discovered site of origin. Read more...

Immunice for Immune Support

http://www.cellmedicine.com stem cell therapy.

Continue reading here:
Stem Cell Therapy for Kidney Failure

A year ago, 9-year-old Kenneth Kelley couldn't read.

Read more:
Stem Cell Treatment Doing Wonders For Autistic Boy

For those still contemplating whether or not the radiation emitted from airport naked body scanners is serious enough to avoid, you may be interested to know that many doctors routinely "opt out" and choose the full-body pat down instead because they recognize the inherent dangers associated with any level of radiation exposure. A recent CNN piece explains that for many doctors, avoiding all sources of radiation whenever possible is just the smart thing to do.

Throughout the past year, was covered many stories related to the US Transportation Security Administration's (TSA) controversial naked body scanners, which are now installed and in use at nearly 80 US airports (http://www.tsa.gov/approach/tech/ait/faqs.shtm). Besides representing an unconstitutional invasion of privacy (http://www.tsa.gov/approach/tech/ait/faqs.shtm), the scanners blast passengers with full-body doses of health-destroying radiation (http://www.dreddyclinic.com/forum/viewtopic.php?f=2&t=22309).

So what do medical doctors who fly have to say about the machines? Well, according to CNN's Elizabeth Cohen who recently conducted her own small investigation, many are concerned about the radiation these scanners emit. Read more...

Joint Mender for Joint Care

In 2011, the world will emit more than 35 billion tons of carbon dioxide. Every day of the year, almost a hundred million tons will be released into the atmosphere. Every second more than a thousand tons – two million pounds – of carbon dioxide is emitted from power plants, cars, trucks, ships, planes, factories, and farms around the world. The average citizen of the world will account for the release of four and a half tons – 9,000 pounds – of CO 2 this year. The average American will be responsible for four times as much, almost 18 tons, or 36,000 pounds of carbon dioxide this year, roughly a hundred pounds of carbon dioxide emissions for every day of the year.

While humans emit far less carbon dioxide than nature, the amount we emit exceeds the capacity of plants and oceans to absorb on top of the amount they’re already absorbing from natural sources. As a result, most of the carbon dioxide we emit remains in the atmosphere. Year over year, the atmospheric concentration of CO 2 creeps up. It will rise only half a percent in 2011, a seemingly tiny change. Yet tiny changes add up. Over the 50 years since 1960, the amount of carbon dioxide in the atmosphere has risen nearly 25%. Since the start of the industrial revolution it has risen by 45%, putting it at a level not seen in millions of years.

[More]

Some 3.2 million Americans have chronic hepatitis C , an infection that can linger in the body for years before producing symptoms. It can eventually lead to serious liver scarring and cancer. And most infections in the U.S. are the disease's particularly tough breed, known as genotype 1, which has a cure rate of less than 40 percent with the best current treatment. [More]

For those still contemplating whether or not the radiation emitted from airport naked body scanners is serious enough to avoid, you may be interested to know that many doctors routinely "opt out" and choose the full-body pat down instead because they recognize the inherent dangers associated with any level of radiation exposure. A recent CNN piece explains that for many doctors, avoiding all sources of radiation whenever possible is just the smart thing to do.

Throughout the past year, was covered many stories related to the US Transportation Security Administration's (TSA) controversial naked body scanners, which are now installed and in use at nearly 80 US airports (http://www.tsa.gov/approach/tech/ait/faqs.shtm). Besides representing an unconstitutional invasion of privacy (http://www.tsa.gov/approach/tech/ait/faqs.shtm), the scanners blast passengers with full-body doses of health-destroying radiation (http://www.dreddyclinic.com/forum/viewtopic.php?f=2&t=22309).

So what do medical doctors who fly have to say about the machines? Well, according to CNN's Elizabeth Cohen who recently conducted her own small investigation, many are concerned about the radiation these scanners emit. Read more...

Joint Mender for Joint Care

In 2011, the world will emit more than 35 billion tons of carbon dioxide. Every day of the year, almost a hundred million tons will be released into the atmosphere. Every second more than a thousand tons – two million pounds – of carbon dioxide is emitted from power plants, cars, trucks, ships, planes, factories, and farms around the world. The average citizen of the world will account for the release of four and a half tons – 9,000 pounds – of CO 2 this year. The average American will be responsible for four times as much, almost 18 tons, or 36,000 pounds of carbon dioxide this year, roughly a hundred pounds of carbon dioxide emissions for every day of the year.

While humans emit far less carbon dioxide than nature, the amount we emit exceeds the capacity of plants and oceans to absorb on top of the amount they’re already absorbing from natural sources. As a result, most of the carbon dioxide we emit remains in the atmosphere. Year over year, the atmospheric concentration of CO 2 creeps up. It will rise only half a percent in 2011, a seemingly tiny change. Yet tiny changes add up. Over the 50 years since 1960, the amount of carbon dioxide in the atmosphere has risen nearly 25%. Since the start of the industrial revolution it has risen by 45%, putting it at a level not seen in millions of years.

[More]